NASDAQ:GTHX

G1 Therapeutics News Headlines

$17.61
-0.46 (-2.55 %)
(As of 07/29/2021 01:45 PM ET)
Add
Compare
Today's Range
$17.61
$18.18
50-Day Range
$17.48
$23.98
52-Week Range
$10.81
$37.07
Volume4,728 shs
Average Volume1.32 million shs
Market Capitalization$740.92 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24

G1 Therapeutics (NASDAQ GTHX) News Headlines Today

SourceHeadline
G1 Therapeutics (GTHX) to Release Quarterly Earnings on WednesdayG1 Therapeutics (GTHX) to Release Quarterly Earnings on Wednesday
americanbankingnews.com - July 29 at 9:56 AM
Analysts Estimate G1 THERAPEUTICS (GTHX) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate G1 THERAPEUTICS (GTHX) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - July 28 at 9:06 PM
G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021
finance.yahoo.com - July 28 at 11:05 AM
G1 Therapeutics, Inc. (NASDAQ:GTHX) Expected to Post Quarterly Sales of $2.70 MillionG1 Therapeutics, Inc. (NASDAQ:GTHX) Expected to Post Quarterly Sales of $2.70 Million
americanbankingnews.com - July 26 at 2:02 AM
 Brokerages Expect G1 Therapeutics, Inc. (NASDAQ:GTHX) to Post -$0.96 Earnings Per Share Brokerages Expect G1 Therapeutics, Inc. (NASDAQ:GTHX) to Post -$0.96 Earnings Per Share
americanbankingnews.com - July 24 at 7:14 PM
 Brokerages Anticipate G1 Therapeutics, Inc. (NASDAQ:GTHX) Will Announce Earnings of -$0.96 Per Share Brokerages Anticipate G1 Therapeutics, Inc. (NASDAQ:GTHX) Will Announce Earnings of -$0.96 Per Share
americanbankingnews.com - July 24 at 7:14 PM
G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast CancerG1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer
finance.yahoo.com - July 19 at 1:28 PM
G1 Therapeutics, Inc. (NASDAQ:GTHX) Director Sells $194,500.00 in StockG1 Therapeutics, Inc. (NASDAQ:GTHX) Director Sells $194,500.00 in Stock
americanbankingnews.com - July 15 at 4:44 PM
G1 Therapeutics, Inc. (NASDAQ:GTHX) Director Mark A. Velleca Sells 10,000 SharesG1 Therapeutics, Inc. (NASDAQ:GTHX) Director Mark A. Velleca Sells 10,000 Shares
americanbankingnews.com - July 15 at 4:44 PM
G1 Therapeutics (NASDAQ:GTHX) Shares Gap Down  After Insider SellingG1 Therapeutics (NASDAQ:GTHX) Shares Gap Down After Insider Selling
americanbankingnews.com - July 15 at 10:22 AM
Insider Selling: G1 Therapeutics, Inc. (NASDAQ:GTHX) Director Sells 10,000 Shares of StockInsider Selling: G1 Therapeutics, Inc. (NASDAQ:GTHX) Director Sells 10,000 Shares of Stock
americanbankingnews.com - July 15 at 4:04 AM
G1 Therapeutics, Inc. (NASDAQ:GTHX) Receives Average Recommendation of "Buy" from AnalystsG1 Therapeutics, Inc. (NASDAQ:GTHX) Receives Average Recommendation of "Buy" from Analysts
americanbankingnews.com - July 11 at 4:12 AM
G1 Therapeutics (NASDAQ:GTHX) Shares Gap Up to $20.80G1 Therapeutics (NASDAQ:GTHX) Shares Gap Up to $20.80
americanbankingnews.com - July 7 at 10:35 AM
Rock star Growth Puts G1 Therapeutics (NASDAQ:GTHX) In A Position To Use DebtRock star Growth Puts G1 Therapeutics (NASDAQ:GTHX) In A Position To Use Debt
finance.yahoo.com - July 6 at 10:56 AM
G1 Therapeutics, Inc. (NASDAQ:GTHX) Expected to Post Quarterly Sales of $2.80 MillionG1 Therapeutics, Inc. (NASDAQ:GTHX) Expected to Post Quarterly Sales of $2.80 Million
americanbankingnews.com - July 5 at 4:08 AM
G1 Therapeutics Announces Addition of Alicia Secor to Board of DirectorsG1 Therapeutics Announces Addition of Alicia Secor to Board of Directors
finance.yahoo.com - June 18 at 1:21 PM
G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation ConferenceG1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference
finance.yahoo.com - June 16 at 10:07 AM
G1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With CoselaG1 Therapeutics Starts Mid-Stage Bladder Cancer Trial With Cosela
markets.businessinsider.com - June 15 at 11:34 PM
G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder CancerG1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer
finance.yahoo.com - June 14 at 8:53 AM
G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung CancerG1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer
finance.yahoo.com - June 4 at 9:08 AM
G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast CancerG1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer
finance.yahoo.com - June 4 at 9:08 AM
G1 Therapeutics, Inc. Common Stock (GTHX)G1 Therapeutics, Inc. Common Stock (GTHX)
nasdaq.com - June 3 at 1:45 PM
G1 Therapeutics(NASDAQ:GTHX) Share Price Is Down 57% Over The Past Three Years.G1 Therapeutics'(NASDAQ:GTHX) Share Price Is Down 57% Over The Past Three Years.
finance.yahoo.com - May 21 at 12:21 PM
G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual MeetingG1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting
finance.yahoo.com - May 19 at 5:27 PM
G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung CancerG1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer
finance.yahoo.com - May 17 at 7:37 AM
G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)
finance.yahoo.com - May 10 at 8:56 AM
G1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2021 Results - Earnings Call TranscriptG1 Therapeutics, Inc. (GTHX) CEO Jack Bailey on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com - May 8 at 12:12 AM
G1 Therapeutics, Inc. (GTHX) Q1 2021 Earnings Call TranscriptG1 Therapeutics, Inc. (GTHX) Q1 2021 Earnings Call Transcript
fool.com - May 6 at 4:34 AM
G1 THERAPEUTICS (GTHX) Reports Q1 Loss, Tops Revenue EstimatesG1 THERAPEUTICS (GTHX) Reports Q1 Loss, Tops Revenue Estimates
finance.yahoo.com - May 5 at 10:02 PM
G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational HighlightsG1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights
finance.yahoo.com - May 5 at 5:01 PM
G1 Therapeutics to Provide First Quarter 2021 Financial Results and Business Update on May 5, 2021G1 Therapeutics to Provide First Quarter 2021 Financial Results and Business Update on May 5, 2021
finance.yahoo.com - April 28 at 2:40 PM
G1 Therapeutics Announces Initiation of Phase 3 Registrational Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC)G1 Therapeutics Announces Initiation of Phase 3 Registrational Study of COSELA™ (trilaciclib) in Triple-Negative Breast Cancer (TNBC)
finance.yahoo.com - April 28 at 9:39 AM
G1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung CancerG1 Therapeutics Announces Publication of Pooled Results from Pivotal Clinical Program of COSELA™ (trilaciclib) in Clinical Lung Cancer
finance.yahoo.com - April 26 at 2:10 PM
Did G1 Therapeutics (NASDAQ:GTHX) Share Price Deserve to Gain 69%?Did G1 Therapeutics' (NASDAQ:GTHX) Share Price Deserve to Gain 69%?
nasdaq.com - April 21 at 9:03 AM
G1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare ConferenceG1 Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference
finance.yahoo.com - April 7 at 7:31 AM
What Kind Of Shareholders Own G1 Therapeutics, Inc. (NASDAQ:GTHX)?What Kind Of Shareholders Own G1 Therapeutics, Inc. (NASDAQ:GTHX)?
finance.yahoo.com - April 6 at 2:52 PM
G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021G1 Therapeutics to Host Virtual COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit on April 9, 2021
benzinga.com - April 1 at 7:49 AM
G1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in OncologyG1 Therapeutics’ COSELA™ (trilaciclib) Included in Two Updated National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology
finance.yahoo.com - March 25 at 8:05 AM
Put Speculative G1 Therapeutics on Your Market Minder ScreenPut Speculative G1 Therapeutics on Your Market Minder Screen
finance.yahoo.com - March 24 at 3:26 PM
Mad Money Lightning Round: Peloton, G1 Therapeutics'Mad Money' Lightning Round: Peloton, G1 Therapeutics
finance.yahoo.com - March 24 at 10:26 AM
G1 Therapeutics Inc. (NASDAQ: GTHX) Featured in Virtual Coverage of the 33rd Annual ROTH ConferenceG1 Therapeutics Inc. (NASDAQ: GTHX) Featured in Virtual Coverage of the 33rd Annual ROTH Conference
marketwatch.com - March 17 at 5:37 AM
G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
finance.yahoo.com - March 5 at 6:28 PM
G1 Therapeutics - Brighter Days AheadG1 Therapeutics - Brighter Days Ahead
seekingalpha.com - March 4 at 12:05 PM
G1 Therapeutics to Participate in Two Investor Conferences in MarchG1 Therapeutics to Participate in Two Investor Conferences in March
finance.yahoo.com - March 3 at 8:36 AM
G1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced MyelosuppressionG1 Therapeutics and Boehringer Ingelheim Announce Commercial Availability of COSELA™ (trilaciclib), the Only FDA-Approved Multilineage Myeloprotection Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression
finance.yahoo.com - March 2 at 9:26 AM
G1 Therapeutics (GTHX) CEO Jack Bailey on Q4 2020 Results - Earnings Call TranscriptG1 Therapeutics' (GTHX) CEO Jack Bailey on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com - February 26 at 1:26 AM
Recap: G1 Therapeutics Q4 EarningsRecap: G1 Therapeutics Q4 Earnings
finance.yahoo.com - February 25 at 12:07 AM
G1 Therapeutics, Inc. (GTHX) Q4 2020 Earnings Call TranscriptG1 Therapeutics, Inc. (GTHX) Q4 2020 Earnings Call Transcript
finance.yahoo.com - February 25 at 12:07 AM
G1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational HighlightsG1 Therapeutics Provides Fourth Quarter and Full Year 2020 Financial Results and Operational Highlights
finance.yahoo.com - February 24 at 7:06 PM
G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021G1 Therapeutics to Provide Fourth Quarter and Full Year 2020 Financial Results and Business Update on February 24, 2021
finance.yahoo.com - February 17 at 8:06 AM
This page was last updated on 7/29/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.